SEC Comment Letter for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105) (NMAD) — Nov 13, 2013
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT, LIXTW) (CIK 0001335105)
Date: Nov. 13, 2013 · CIK: 0001335105 · Accession: 0000000000-13-062224
AI Filing Summary & Sentiment
Reasoning
Letter
November 1 3, 2013 Via E -mail John S. Kovach Chief Executive Officer and Chief Financial Officer Lixte Biotechnology Holdings, Inc. 248 Route 25A, No. 2 East Setauket, New York 11733
Re: Lixte Biotechnology Holdings , Inc. Annual Report on Form 10-K for the Fiscal Year ended December 31, 2012 Filed March 15, 2013 File No. 00 0-51476
Dear Mr. Kovach :
We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Com mission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Excha nge Act of 1934 and all applicable rules require.
Sincerely,
/s/ Daniel Greenspan for
Show Raw Text
November 1 3, 2013 Via E -mail John S. Kovach Chief Executive Officer and Chief Financial Officer Lixte Biotechnology Holdings, Inc. 248 Route 25A, No. 2 East Setauket, New York 11733 Re: Lixte Biotechnology Holdings , Inc. Annual Report on Form 10-K for the Fiscal Year ended December 31, 2012 Filed March 15, 2013 File No. 00 0-51476 Dear Mr. Kovach : We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Com mission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Excha nge Act of 1934 and all applicable rules require. Sincerely, /s/ Daniel Greenspan for Jeffrey P. Riedler Assistant Director cc: David L. Ficksman, Esq. TroyGould 1801 Century Park East, Suite 1600 Los Angeles, CA 90067